Business Context and Reporting Period
Tenaya Therapeutics, Inc. (TNYA) is a clinical-stage biotechnology company focused on developing curative therapies for heart disease, specifically targeting genetic cardiomyopathies and heart failure. The reporting period covers the fiscal year ended December 31, 2025. The company is classified as an emerging growth company and a smaller reporting company. Its primary pipeline includes TN-201 (gene therapy for MYBPC3-associated HCM), TN-401 (gene therapy for PKP2-associated ARVC), and TN-301 (small molecule HDAC6 inhibitor for HFpEF and DMD).
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(90.6) million | $(111.1) million |
| Operating Expenses | $(93.3) million | $(115.9) million |
| Research & Development | $(68.6) million | $(86.7) million |
| General & Administrative | $(24.7) million | $(29.2) million |
| Cash, Cash Equivalents & Investments | $100.5 million | $61.4 million |
| Accumulated Deficit | $(605.0) million | $(514.4) million |
| Net Cash Used in Operating Activities | $(68.3) million | $(90.5) million |
| Net Cash Provided by Financing Activities | $108.4 million | $47.7 million |
Note: The company has not generated any product revenue to date. Margins are not applicable due to zero revenue.
Material Changes vs. Prior Period
- Expense Reduction: Total operating expenses decreased by 20% ($22.6 million) compared to 2024. This was driven by workforce reductions initiated in March 2025 and May 2024, resulting in lower employee-related costs, clinical support costs, and manufacturing expenses.
- Capital Raising: The company significantly increased its cash position through two major follow-on offerings in 2025 (March and December), raising net proceeds of approximately $105.1 million combined. This contrasts with $46.8 million raised in 2024.
- Manufacturing Strategy: In 2025, the company decided to decommission its internal Genetic Medicines Manufacturing Center (GMMC) to support cost containment, relying instead on a combination of internal capabilities and external CDMOs.
- Grant Recognition: The company recognized $2.5 million as a reduction of R&D expenses related to an $8.0 million grant from the California Institute for Regenerative Medicine (CIRM) awarded in February 2025.
Guidance, Outlook, and Risks
Outlook and Milestones:
- TN-201 (HCM): The company expects to present longer-term Cohort 1 and interim Cohort 2 data in the first half of 2026. Two-year Cohort 1 data is anticipated in the second half of 2026. The company intends to pursue regulatory alignment on pivotal trial plans.
- TN-401 (ARVC): One-year Cohort 1 data and initial Cohort 2 data are expected in the first half of 2026, with interim Cohort 2 results in the second half. Regulatory alignment on pivotal trials is also planned.
- TN-301 (HFpEF/DMD): The company is seeking a strategic partner for late-stage development and commercialization in large indications like HFpEF. Preclinical data presented in 2026 showed efficacy in DMD models.
New Collaboration:
- In March 2026, Tenaya entered a multi-target research collaboration with Alnylam Pharmaceuticals. Alnylam will pay an upfront payment of up to $10.0 million and is eligible to pay up to $1.13 billion in milestones. The collaboration focuses on identifying and validating novel gene targets for cardiovascular disease.
Liquidity:
- Management believes existing cash, cash equivalents, and investments ($100.5 million as of Dec 31, 2025) are sufficient to fund operations for at least the next twelve months.
Risks and Contingencies:
- Nasdaq Listing: The company received notice in April 2025 that it did not meet the minimum bid price requirement ($1.00) for continued listing on Nasdaq. It has a 180-day grace period to regain compliance.
- Regulatory Holds: The FDA previously placed the MyPEAK-1 trial on clinical hold in November 2025 regarding immunosuppression management; the hold was lifted within six weeks.
- Capital Needs: The company expects to continue incurring significant losses and will require substantial additional funding to complete development and commercialization.
Investor Verification Checklist
- Cash Runway: Verify if the $100.5 million cash balance is sufficient to fund the planned 2026 data readouts and potential pivotal trial designs without immediate dilution.
- Nasdaq Compliance: Monitor the stock price to ensure it meets the $1.00 minimum bid price requirement within the 180-day grace period to avoid delisting.
- Alnylam Collaboration Terms: Review the definitive agreement for the Alnylam collaboration to confirm the exact upfront payment amount and milestone triggers.
- Clinical Data Readouts: Track the timing and results of the H1 2026 data presentations for TN-201 and TN-401, which are critical for regulatory alignment.
- Manufacturing Transition: Assess the impact of decommissioning the GMMC facility on future supply chain costs and timelines for scaling up production.